Market Overview:
The global liver cirrhosis therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising incidence of liver cirrhosis, increasing awareness about available treatment options, and growing demand for novel therapies. Based on type, the global liver cirrhosis therapeutics market is segmented into oral and injection therapies. Oral therapies are further sub-segmented into small molecules and biologics. Injection therapies are further sub-segmented into monoclonal antibodies (mAbs) and other therapeutic agents. Small molecules held the largest share of the oral therapy segment in 2017 owing to their high efficacy and safety profile as compared to biologics. However, biologics are expected to witness higher growth during the forecast period due to their ability to target specific proteins associated with various diseases including liver cirrhosis.
Product Definition:
Liver cirrhosis therapeutics is a treatment for liver cirrhosis, a condition in which the liver becomes scarred and its function is impaired. The most important use of liver cirrhosis therapeutics is to improve the patient's quality of life by reducing symptoms and preventing or reversing the progression of the disease.
Oral:
Oral is a form of medication administration through the mouth. It can be used with injections, inhalation therapies or oral dosage forms. The most common route of drug delivery is through the mouth using tablets, capsules or liquids.
The global oral segment accounted for USD 6,100 million in 2014.
Injection:
Injection is a medication method used to deliver medicine in the body. Injection can be oral, parenteral or transdermal. The choice of injection depends on the type of disease and area that needs to be treated. There are various types of injections available in the market for different diseases such as anti-infective, analgesic, anesthetic and anti-inflammatory among others which are used by physicians across the globe according to their specialty.
Application Insights:
Based on the application, the liver cirrhosis therapeutics market is segmented into hospital-based, clinic-based and others. The hospital based segment held a major share in 2017 owing to high prevalence of chronic liver diseases that require long term management. On the other hand, clinic based segment is expected to witness lucrative growth over the forecast period due to increasing awareness about available treatment options and availability of efficient services among patients with similar concerns.
The others application category includes home healthcare and non-residential settings that offer care for acute as well as chronic liver disorders. Increasing number of such facilities at regional level as well as globally has positively impacted market growth in this segment over recent years.
Regional Analysis:
Europe dominated the global liver cirrhosis therapeutics market in 2017. The presence of a large number of manufacturers and suppliers, high healthcare expenditure, better reimbursement scenario, and growing patient awareness levels are some factors responsible for its largest share. In addition, the adoption of new technologies is also expected to drive growth during the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels and improving economic conditions in emerging countries such as China & India. Furthermore, increasing prevalence of hepatitis B & C virus infections due to lack of hygiene & sanitation coupled with social changes will further boost revenue generation in this region during the estimated time span from 2018-2030 (Ref).
Growth Factors:
- Increasing incidence of liver cirrhosis due to rising alcohol consumption and hepatitis C infections
- Growing demand for better treatment options for liver cirrhosis
- Rising awareness about the available treatment options for liver cirrhosis
- increasing investment in research and development of new drugs for the treatment of liver cirrhosis
- growing number of clinical trials being conducted on new drugs for the treatment of liver cirrhosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Liver Cirrhosis Therapeutics Market Research Report
By Type
Oral, Injection
By Application
Hospital, Clinic, Others
By Companies
Gilead Sciences, GlaxoSmithKline, Johnson and Johnson, Merck, Roche, Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, Gilead Sciences, Norgine, Pharmicell, Salix Pharmaceuticals, Stempeutics Research
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Liver Cirrhosis Therapeutics Market Report Segments:
The global Liver Cirrhosis Therapeutics market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- GlaxoSmithKline
- Johnson and Johnson
- Merck
- Roche
- Bristol-Myers Squibb
- Conatus Pharmaceuticals
- Gwo Xi Stem Cell Applied Technology
- Instituto Grifols
- Intercept Pharmaceuticals
- Gilead Sciences
- Norgine
- Pharmicell
- Salix Pharmaceuticals
- Stempeutics Research
Highlights of The Liver Cirrhosis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liver Cirrhosis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liver cirrhosis therapies are medications and treatments used to help improve the health of someone with liver cirrhosis. These therapies may include medication, surgery, or a combination of both.
Some of the major companies in the liver cirrhosis therapeutics market are Gilead Sciences, GlaxoSmithKline, Johnson and Johnson, Merck, Roche, Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, Gilead Sciences, Norgine, Pharmicell, Salix Pharmaceuticals, Stempeutics Research.
The liver cirrhosis therapeutics market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Liver Cirrhosis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Liver Cirrhosis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Liver Cirrhosis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Liver Cirrhosis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Liver Cirrhosis Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Liver Cirrhosis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Liver Cirrhosis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Liver Cirrhosis Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Liver Cirrhosis Therapeutics Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Liver Cirrhosis Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Liver Cirrhosis Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Liver Cirrhosis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Liver Cirrhosis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Liver Cirrhosis Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Liver Cirrhosis Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Liver Cirrhosis Therapeutics Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Liver Cirrhosis Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Liver Cirrhosis Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Liver Cirrhosis Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Liver Cirrhosis Therapeutics Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Liver Cirrhosis Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Liver Cirrhosis Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Liver Cirrhosis Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Liver Cirrhosis Therapeutics Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Liver Cirrhosis Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Liver Cirrhosis Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Liver Cirrhosis Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Liver Cirrhosis Therapeutics Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Liver Cirrhosis Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Liver Cirrhosis Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Liver Cirrhosis Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Liver Cirrhosis Therapeutics Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Liver Cirrhosis Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Liver Cirrhosis Therapeutics Market: Competitive Dashboard
14.2 Global Liver Cirrhosis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences
14.3.2 GlaxoSmithKline
14.3.3 Johnson and Johnson
14.3.4 Merck
14.3.5 Roche
14.3.6 Bristol-Myers Squibb
14.3.7 Conatus Pharmaceuticals
14.3.8 Gwo Xi Stem Cell Applied Technology
14.3.9 Instituto Grifols
14.3.10 Intercept Pharmaceuticals
14.3.11 Gilead Sciences
14.3.12 Norgine
14.3.13 Pharmicell
14.3.14 Salix Pharmaceuticals
14.3.15 Stempeutics Research
